Welcome to our dedicated page for SRNG news (Ticker: SRNG), a resource for investors and traders seeking the latest updates and insights on SRNG stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SRNG's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SRNG's position in the market.
On September 17, 2021, Ginkgo Bioworks and Soaring Eagle Acquisition Corp. announced the successful closure of their business combination. The newly formed entity, Ginkgo Bioworks Holdings, Inc., will trade on the NYSE under the symbols 'DNA' and 'DNA.WS'. This transaction, approved by Soaring Eagle stockholders on September 14, 2021, yields over $1.6 billion in proceeds and establishes Ginkgo's enterprise value at $15 billion. Ginkgo aims to leverage its cell programming platform to revolutionize various industries and address global challenges.
Soaring Eagle Acquisition Corp. announced shareholder approval for its business combination with Ginkgo Bioworks, with 97% in favor and 75% participating in the vote. The transaction is set to close on
Ginkgo Bioworks announced the launch of Ayana Bio, aimed at producing bioactive compounds for complementary medicine. This initiative is supported by a $30 million Series A funding round led by Viking Global Investors and Cascade Investment. The new venture seeks to provide standardized and reliable medicinal bioactives to address global health needs, tapping into a combined market exceeding $400 billion. The launch aligns with Ginkgo's strategy to expedite product development through its cell programming platform.
On September 9, 2021, Ginkgo Bioworks launched Verb Biotics, a company focused on innovating probiotics for human health. This initiative comes as Ginkgo prepares for its business combination with Soaring Eagle Acquisition Corp. (Nasdaq: SRNG). Verb aims to design new probiotic strains to tackle challenges like limited shelf life while tapping into a rapidly growing $50 billion global probiotics market. The launch is backed by $30 million in Series A funding from Viking Global Investors and Cascade Investment. Ginkgo's expertise in cell programming will be key to Verb's success.
Soaring Eagle Acquisition Corp. has announced that its extraordinary general meeting will take place on September 14, 2021, where shareholders are expected to approve the business combination with Ginkgo Bioworks, Inc. The transaction's closing is anticipated on September 16, 2021, with the combined company's stock trading under the ticker symbol 'DNA' on September 17, 2021. This merger aims to transform Ginkgo Bioworks into a public entity, enabling growth in biotechnology sectors.
Tantu has partnered with Ginkgo Bioworks to accelerate research and development of living biotherapeutics aimed at treating gastrointestinal diseases. This collaboration will leverage Ginkgo's automated platform to expedite Tantu's therapeutic gene development, addressing the needs of over 62 million Americans suffering from digestive disorders. Tantu's engineered microbe aims to enhance gut barrier function and mucosal healing, potentially revolutionizing treatment options. Completion of Ginkgo's recent business combination with Soaring Eagle Acquisition Corp. (Nasdaq: SRNG) is anticipated soon.
Ginkgo Bioworks announced its participation in upcoming virtual conferences as it progresses towards a business combination with Soaring Eagle Acquisition Corp. (Nasdaq: SRNG). The key events include the Morgan Stanley Healthcare Conference on September 9, Wells Fargo Healthcare Conference on September 10, and Bernstein ESG Conference on September 15, 2021. Webcasts of the presentations will be available on Ginkgo's investor relations website. The business combination aims to establish Ginkgo as a public company, with a shareholder meeting set for September 14, 2021.
Cambium Biomaterials has partnered with Ginkgo Bioworks to enhance the development and commercialization of high-performance biomaterials. This collaboration aims to utilize Ginkgo's advanced bioengineering capabilities to explore bio-based molecules, focusing on materials with improved protection against heat, flame, and sensors. The partnership signifies Ginkgo's deeper engagement in the biomaterials sector, following its planned business combination with Soaring Eagle Acquisition Corp. (SRNG). The deal is expected to bolster Cambium's product pipeline and accelerate its market introduction timeline.
Soaring Eagle Acquisition Corp. (SRNGU) has announced its intention to voluntarily withdraw its Class A ordinary shares and warrants from Nasdaq and list on the New York Stock Exchange following its business combination with Ginkgo Bioworks, Inc. The company's jurisdiction of incorporation will change from the Cayman Islands to Delaware, and it will be renamed Ginkgo Bioworks Holdings, Inc., with new trading symbols DNA and DNA.WS. The transition to NYSE aims to align with other innovative companies, contingent upon the successful completion of the business combination.
